Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Preprint |
| Published: |
2026
|
| Subjects: | |
| Online Access: | https://arxiv.org/abs/2604.09197 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866914463439912960 |
|---|---|
| author | Fati, Francesca Coutinho, Felipe Reinius, Marika Rosanu, Marina Funingana, Gabriel De Vitis, Luigi Schivardi, Gabriella Clayton, Hannah Traversa, Alice Gao, Zeyu Penteado, Guilherme Gao, Shangqi Pastori, Francesco Woitek, Ramona Ghioni, Maria Cristina Aletti, Giovanni Damiano Jimenez-Linan, Mercedes Burge, Sarah Colombo, Nicoletta Sala, Evis Spadea, Maria Francesca Kline, Timothy L. Brenton, James D. Cardoso, Jaime Multinu, Francesco De Momi, Elena Crispin-Ortuzar, Mireia Machado, Ines P. |
| author_facet | Fati, Francesca Coutinho, Felipe Reinius, Marika Rosanu, Marina Funingana, Gabriel De Vitis, Luigi Schivardi, Gabriella Clayton, Hannah Traversa, Alice Gao, Zeyu Penteado, Guilherme Gao, Shangqi Pastori, Francesco Woitek, Ramona Ghioni, Maria Cristina Aletti, Giovanni Damiano Jimenez-Linan, Mercedes Burge, Sarah Colombo, Nicoletta Sala, Evis Spadea, Maria Francesca Kline, Timothy L. Brenton, James D. Cardoso, Jaime Multinu, Francesco De Momi, Elena Crispin-Ortuzar, Mireia Machado, Ines P. |
| contents | Purpose. High-grade serous ovarian carcinoma (HGSOC) is characterized by pronounced biological and spatial heterogeneity and is frequently diagnosed at an advanced stage. Neoadjuvant chemotherapy (NACT) followed by delayed primary surgery is commonly employed in patients unsuitable for primary cytoreduction. The Chemotherapy Response Score (CRS) is a validated histopathological biomarker of response to NACT, but it is only available postoperatively. In this study, we investigate whether pre-treatment computed tomography (CT) imaging and clinical data can be used to predict CRS as an investigational decision-support adjunct to inform multidisciplinary team (MDT) discussions regarding expected treatment response. Methods. We proposed a 2.5D multimodal deep learning framework that processes lesion-dense omental slices using a pre-trained Vision Transformer encoder and integrates the resulting visual representations with clinical variables through an intermediate fusion module to predict CRS. Results. Our multimodal model, integrating imaging and clinical data, achieved a ROC-AUC of 0.95 alongside 95% accuracy and 80% precision on the internal test cohort (IEO, n=41 patients). On the external test set (OV04, n=70 patients), it achieved a ROC-AUC of 0.68, alongside 67% accuracy and 75% precision. Conclusion. These preliminary results demonstrate the feasibility of transformer-based deep learning for preoperative prediction of CRS in HGSOC using routine clinical data and CT imaging. As an investigational, pre-treatment decision-support tool, this approach may assist MDT discussions by providing early, non-invasive estimates of treatment response. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2604_09197 |
| institution | arXiv |
| publishDate | 2026 |
| record_format | arxiv |
| spellingShingle | Vision Transformers for Preoperative CT-Based Prediction of Histopathologic Chemotherapy Response Score in High-Grade Serous Ovarian Carcinoma Fati, Francesca Coutinho, Felipe Reinius, Marika Rosanu, Marina Funingana, Gabriel De Vitis, Luigi Schivardi, Gabriella Clayton, Hannah Traversa, Alice Gao, Zeyu Penteado, Guilherme Gao, Shangqi Pastori, Francesco Woitek, Ramona Ghioni, Maria Cristina Aletti, Giovanni Damiano Jimenez-Linan, Mercedes Burge, Sarah Colombo, Nicoletta Sala, Evis Spadea, Maria Francesca Kline, Timothy L. Brenton, James D. Cardoso, Jaime Multinu, Francesco De Momi, Elena Crispin-Ortuzar, Mireia Machado, Ines P. Computer Vision and Pattern Recognition Artificial Intelligence Purpose. High-grade serous ovarian carcinoma (HGSOC) is characterized by pronounced biological and spatial heterogeneity and is frequently diagnosed at an advanced stage. Neoadjuvant chemotherapy (NACT) followed by delayed primary surgery is commonly employed in patients unsuitable for primary cytoreduction. The Chemotherapy Response Score (CRS) is a validated histopathological biomarker of response to NACT, but it is only available postoperatively. In this study, we investigate whether pre-treatment computed tomography (CT) imaging and clinical data can be used to predict CRS as an investigational decision-support adjunct to inform multidisciplinary team (MDT) discussions regarding expected treatment response. Methods. We proposed a 2.5D multimodal deep learning framework that processes lesion-dense omental slices using a pre-trained Vision Transformer encoder and integrates the resulting visual representations with clinical variables through an intermediate fusion module to predict CRS. Results. Our multimodal model, integrating imaging and clinical data, achieved a ROC-AUC of 0.95 alongside 95% accuracy and 80% precision on the internal test cohort (IEO, n=41 patients). On the external test set (OV04, n=70 patients), it achieved a ROC-AUC of 0.68, alongside 67% accuracy and 75% precision. Conclusion. These preliminary results demonstrate the feasibility of transformer-based deep learning for preoperative prediction of CRS in HGSOC using routine clinical data and CT imaging. As an investigational, pre-treatment decision-support tool, this approach may assist MDT discussions by providing early, non-invasive estimates of treatment response. |
| title | Vision Transformers for Preoperative CT-Based Prediction of Histopathologic Chemotherapy Response Score in High-Grade Serous Ovarian Carcinoma |
| topic | Computer Vision and Pattern Recognition Artificial Intelligence |
| url | https://arxiv.org/abs/2604.09197 |